Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Congressional Drug Pricing Investigation Receives Boost From Rep. Bliley

  • News

Executive Summary

Congressional investigation of drug pricing is receiving support from an unlikely source, House Commerce Committee Chair Bliley (R-Va.)

You may also be interested in...



Oncology Rx Pricing Focus Shifts To Medicaid: House Cmte. Seeks Documents

The passage of AWP reform in Medicare will not end Congressional scrutiny of the oncologic drug market

Oncology Rx Pricing Focus Shifts To Medicaid: House Cmte. Seeks Documents

The passage of AWP reform in Medicare will not end Congressional scrutiny of the oncologic drug market

Warrick Albuterol Medicaid "Overpayments" Total $14.6 Mil. -Texas Argues

Warrick Pharmaceuticals is responsible for $14.6 mil. in albuterol reimbursement overpayments made by the Texas Medicaid Program, Texas Attorney General John Cornyn argued in a lawsuit filed Sept. 7 in Travis County, Texas state court.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS036023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By